- Leave employer health insurance in place.
- A public option for health insurance.
- Mandatory health insurance in the same way there's mandatory auto insurance.
- An insurance exchange to give individuals and small business mass buying power.
... the hundreds of billions of dollars in waste and fraud, as well as unwarranted subsidies in Medicare that go to insurance companiesUnsurprisingly, PhRMA is firmly behind the president, while stocks in healthcare insurers are on a rollercoaster ride.
PhRMA's pledge to support the Obama plan is heavily dependent on an agreement that the industry will give up $80 billion to help pay for it.
It will be interesting to see if PhRMA continues to support the president even if Democrats slip a Medicare negotiation clause into the eventual bill that passes. Drug companies might want to think carefully before abandoning the plan if that happens. Here's why:
Look at the four pieces of Obama's plan. It leaves in place the current system (which has been enormously profitable for drug companies) but adds three new systems in which consumers can get prescription coverage. That, right there, is several billion in extra revenues for drug companies.
Secondly, and in the long-term more importantly, the new institutions Obama proposes will have to do the same things that the old ones -- insurers and the government -- have been doing: negotiate drug prices with drug companies.
In drug price negotiations, drug companies always have the advantage. The companies have to negotiate with all the institutions, but each institution only has the knowledge of their own negotiations. In other words, the new market that Obama proposes creates a larger group of consumers who are more splintered when it comes to negotiating prices; and they will face drug companies who will have a complete knowledge of the entire universe of drug -price negotiation.
In betting who gets the better deal out of those negotiations, my money will be on the drug companies, Medicare price negotiations or no.
Photo by Flickr user Jon Person, CC.
- Sanofi Also Linked to FreedomWorks, Group That Urged Healthcare Town Hall Disruptions; Armey Quits DLA Piper
- BMS, DLA Piper Distance Selves From Healthcare Town Hall Disruptions
- UPDATED: BMS Funded Anti-Reform Group But Its Execs Keep Health Coverage After Layoffs
- The Dog Ate My Homework: Medicines Co. Lobbied Against Deadlines, Not Healthcare Reform
- UPDATED: BMS Had $400M Motive to Use Healthcare Town Hall Rioters
- Claim: BMS, The Medicines Co., Funded Healthcare Town Hall Riot Group
- Amgen, GSK Lobby on Healthcare as Execs Enjoy Luxury Benefits
- As Lilly, Pfizer Lobby Against Obama Healthcare Plan, Their Execs Enjoy Gold-Plated Coverage
- Pharma Lobbying Money: Who's Spending What Fighting Healthcare Reform
- Lilly, Pfizer and AstraZeneca Jockeying for Position on Healthcare Reform
- Lilly CEO Lechleiter and PhRMA's Boogeyman: a "Government-Run Plan"
- Claim: AstraZeneca CEO Brennan's Pay Too High; Spends Too Much on Lobbying
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration